Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9605020 | 1.00 | PRCP (0.47) | PRCPHCRTR1HCRTR2CHEK2PTGES | |
| SCHEMBL12509692 | 0.99 | HCRTR1 (0.46) | PRCPHCRTR1HCRTR2CHEK2PTGES | |
| SCHEMBL19400826 | 0.96 | PRCP (0.52) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL19400821 | 0.96 | PRCP (0.52) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL12565516 | 0.96 | HCRTR1 (0.45) | PRCPHCRTR1HCRTR2CHEK2 | |
| SCHEMBL12509701 | 0.96 | CHEK2 (0.46) | PRCPHCRTR1HCRTR2CHEK2PTGES | |
| SCHEMBL9605022 | 0.95 | PRCP (0.44) | PRCPHCRTR1HCRTR2CHEK2PTGES | |
| SCHEMBL2757482 | 0.95 | HCRTR1 (0.49) | HCRTR1HCRTR2CHEK2 | |
| SCHEMBL2192539 | 0.93 | HCRTR1 (0.48) | PRCPHCRTR1HCRTR2 | |
| SCHEMBL11924830 | 0.92 | HCRTR1 (0.42) | PRCPHCRTR1HCRTR2CHEK2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8623899-B2 | Bis-benzimidazole derivatives as hepatitis C virus inhibitors | Janssen Research & Development Ireland (IE) | 2014-01-07 | — | — | US | disclosed |
| US-8623899-B2 | Bis-benzimidazole derivatives as hepatitis C virus inhibitors | Janssen Research & Development Ireland (IE) | 2014-01-07 | — | — | US | disclosed |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC (US) | 2013-11-07 | — | — | US | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2012-05-31 | — | — | US | disclosed |
| WO-2011050146-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | PRCP 1178/4885HCRTR1 4644/4885HCRTR2 4792/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | PRCP 1075/4885HCRTR1 4358/4885HCRTR2 4746/4885 |
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | HAVCR2, ZC3HAV1, CCNI | PRCP 2043/4885HCRTR1 3448/4885HCRTR2 4538/4885 |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | PRCP 1075/4885HCRTR1 4358/4885HCRTR2 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.